Oncology shift toward personalized mRNA-based combination therapies

Medical experts indicate that the development of a singular cancer vaccine is unlikely, favoring a transition to modular mRNA platforms for patient-specific treatments. This shift represents a move away from mass-produced oncology solutions toward highly tailored, combination-based therapeutic approaches.